AZD6615 / AstraZeneca - LARVOL DELTA

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects (clinicaltrials.gov) - P1; N=24; Terminated; Sponsor: AstraZeneca; N=72 ➔ 24; Trial completion date: Nov 2021 ➔ Feb 2020; Recruiting ➔ Terminated; Trial primary completion date: Nov 2021 ➔ Feb 2020; It was decided to not run the Japanese cohorts in the study.

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Dyslipidemia • Metabolic Disorders

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: AstraZeneca; Trial completion date: Aug 2021 ➔ Nov 2021; Trial primary completion date: Aug 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Dyslipidemia • CLU • CRP • CST3 • F2 • KIM1 • LCN2 • Osteopontin • SPP1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: AstraZeneca

Clinical • New P1 trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: AstraZeneca; Trial completion date: Feb 2021 ➔ Sep 2021; Trial primary completion date: Feb 2021 ➔ Sep 2021

Clinical • Trial completion date • Trial primary completion date